Abstract:Intrahepatic cholangiocarcinoma (iCCA) has over the last 10-20 years become the focus of increasing concern, largely due to its rising incidence and high mortality rates worldwide. The significant increase in mortality rates from this primary hepatobiliary cancer, particularly over the past decade, has coincided with a rapidly growing interest among clinicians, investigators, and patient advocates to seek greater mechanistic insights and more effective biomarker-driven targeted approaches for managing and/or preventing this challenging liver cancer. In addition to discussing challenges posed by this aggressive cancer, this review will emphasize recent epidemiological, basic, and translational research findings for iCCA. In particular, we will highlight emerging demographic changes and evolving risk factors, the critical role of the tumor microenvironment, extracellular vesicle biomarkers and therapeutics, intertumoral and intratumoral heterogeneity, and current and emerging targeted therapies regarding iCCA. Specifically, recent evidence linking non-bile duct medical conditions, such as nonalcoholic fatty liver disease and nonspecific cirrhosis, to intrahepatic cholangiocarcinogenesis together with geographic and ethnic variation will be assessed. Recent developments concerning the roles played by transforming growth factor-β and platelet-derived growth factor D in driving the recruitment and expansion of cancer-associated myofibroblasts within cholangiocarcinoma (CCA) stroma as well as their therapeutic implications will also be discussed. In addition, the potential significance of extracellular vesicles as bile and serum biomarkers and therapeutic delivery systems for iCCA will be described. An integrated systems approach to classifying heterogeneous iCCA subtypes will be further highlighted, and recent clinical trials and emerging targeted therapies will be reviewed, along with recommendations for future translational research opportunities. Established international CCA networks are now facilitating collaborations aimed at advancing iCCA translational and clinical research.

Translational Bioinformatics for Cholangiocarcinoma: Opportunities and Challenges

Computational Advances in Cancer Informatics (A)

Microarray bioinformatics in cancer- a review

Dissecting cellular heterogeneity and intercellular communication in cholangiocarcinoma: implications for individualized therapeutic strategies

Intrahepatic Cholangiocarcinoma: Continuing Challenges and Translational Advances

Immunotherapy and Targeted Therapy for Cholangiocarcinoma: Artificial Intelligence Research in Imaging

Translational Medicine in Hepatocellular Carcinoma

Big data in basic and translational cancer research

The molecular biology of pancreatic adenocarcinoma: translational challenges and clinical perspectives

Immunotherapy of cholangiocarcinoma: Therapeutic strategies and predictive biomarkers

Genomic and Transcriptomic Landscape of Tumor Clonal Evolution in Cholangiocarcinoma.

Application of AI on cholangiocarcinoma

Artificial intelligence and cholangiocarcinoma: Updates and prospects

Bioinformatics approaches for anti-cancer drug discovery.

Bioinformatics tools and resources for cancer and application

The molecular mechanisms and targeting strategies of transcription factors in cholangiocarcinoma

New Progression and Direction of Translational Medicine on Colorectal Cancer

Application of Informatics in Cancer Research and Clinical Practice: Opportunities and Challenges

Translational Bioinformatics and Computational Systems Medicine

Data-driven translational prostate cancer research: from biomarker discovery to clinical decision

Immune infiltration and a ferroptosis-related gene signature for predicting the prognosis of patients with cholangiocarcinoma